enGene Therapeutics Inc (ENGN) Stock AnalysisENGNenGene Therapeutics Inc

enGene Therapeutics Inc., formerly enGene Holdings Inc., is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA). It operates in the Healthcare sector.

enGene Holdings Inc is not a good buy right now due to significant financial losses and analyst downgrades. The current price is $1.825, and the company reported a net loss of $30.23 million for Q2 2026. The forward P/E ratio is 0, indicating no earnings expected in the near term, which raises concerns about its profitability and growth potential.